Keros Therapeutics, Inc. (KROS) vs Entrada Therapeutics, Inc. (TRDA)

A side-by-side comparison of Keros Therapeutics, Inc. and Entrada Therapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

KROS

Keros Therapeutics, Inc.

$218M

$11.01HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT

TRDA

Entrada Therapeutics, Inc.

$210M

$5.42HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT

Total return — KROS vs TRDA

growth of $100 · dividends reinvested · last 5y

KROS -72.4% (-22.7%/yr)TRDA -77.1% (-25.5%/yr)KROS compounded faster over this window

KROS TRDA

KROS vs TRDA: by the numbers

•KROS is the larger company ($218M vs $210M market cap).
•Both run net losses; KROS's is the smaller (-553.88% vs -3537.73% net margin).

Metrics side by side

Valuation

Metric	KROS	TRDA
P/S ratio	14.54	44.90
P/B ratio	0.83	0.90

Profitability

Metric	KROS	TRDA
Gross margin	94.68%	83.89%
Operating margin	28.94%	-613.66%
Net margin	-553.88%	-3537.73%
ROE	-31.70%	-71.02%
ROIC	-36.49%	-63.61%

Growth (annualized)

Metric	KROS	TRDA
Revenue CAGR (5Y)	172.50%	N/A
Total return CAGR (5Y)	-21.98%	N/A

Go deeper

Full KROS analysis Full TRDA analysis Interactive comparison tool

Dig into the metrics

Keros Therapeutics ROE Entrada Therapeutics ROE Keros Therapeutics operating margin Entrada Therapeutics operating margin Keros Therapeutics revenue growth Entrada Therapeutics revenue growth Keros Therapeutics free cash flow Entrada Therapeutics free cash flow

Keros Therapeutics & Entrada Therapeutics appear in these rankings

Fastest Revenue Growth Stocks

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.